Peptide Half-Lives Explained: Complete Reference Guide (With Calculator)

When researchers design peptide protocols, one of the most critical—yet frequently misunderstood—variables is half-life. The difference between a peptide with a 2-minute half-life and one with a 7-day half-life isn't just a scheduling detail; it's a fundamental pharmacokinetic distinction that determines everything from administration frequency to biological activity windows.

This reference guide explains what peptide half-life actually means, the key factors that determine it, and provides a comprehensive reference table covering 25+ commonly researched peptides. For hands-on calculations, use the Peptides.SO dose plotter and half-life calculator.

Research Purposes Disclaimer: All peptides discussed in this guide are for laboratory research purposes only. This content is educational and does not constitute medical advice. Peptide research should be conducted by qualified researchers in compliance with applicable regulations.

Looking for practical dosing frequency and post-reconstitution storage timelines instead of the full reference table? See our Peptide Half-Life & Stability Guide: How Dosing Frequency Relates to Peptide Degradation (2026).

What Is Peptide Half-Life?

In pharmacokinetics, half-life (t½) refers to the time required for the concentration of a substance in biological fluid—typically plasma—to reduce to half its original value. For peptides, this definition comes with important nuances.

Half-life is not the same as duration of action. A peptide may be cleared from plasma within minutes while its downstream biological effects—receptor activation, gene expression changes, signaling cascades—persist for hours or even days. This distinction is especially important for research peptides like BPC-157, which has a plasma half-life measured in minutes but triggers regenerative signaling pathways that researchers observe over much longer timeframes.

Phase Kinetics: Alpha and Beta Half-Life

Many peptides display two-phase clearance:

• Alpha (α) phase: Rapid initial distribution from plasma into tissues. This phase is often very short—minutes to an hour.
• Beta (β) phase: Slower elimination as the peptide is metabolized and excreted. This is typically what's reported as the "half-life."

When researchers cite a half-life figure for a research peptide, they are usually referencing the terminal elimination half-life (beta phase), unless otherwise specified.

How Peptide Half-Life Differs from Small Molecules

Traditional small-molecule drugs are metabolized primarily by liver enzymes (CYP450 system) and excreted renally. Peptides follow a different fate:

• Proteolytic degradation: Peptidases and proteases throughout the body—in plasma, the liver, kidneys, and gastrointestinal tract—cleave peptide bonds, rapidly breaking down unmodified sequences.
• Renal filtration: Small peptides (under ~5 kDa) are filtered by the glomerulus and broken down further by tubular brush-border enzymes.
• Receptor-mediated endocytosis: Peptides bound to receptors may be internalized and degraded intracellularly.

This susceptibility to proteolysis is why most unmodified research peptides have dramatically shorter half-lives than small-molecule drugs—and why pharmaceutical engineers invest heavily in structural modifications to extend plasma stability.

Key Factors That Determine Peptide Half-Life

1. Amino Acid Composition and Sequence

The primary sequence profoundly affects stability. Peptides containing certain cleavage motifs are rapidly degraded by specific proteases:

• Dipeptidyl peptidase-4 (DPP-4) rapidly cleaves GLP-1 at the Ala-Glu bond, explaining native GLP-1's ~2-minute half-life
• Proline-containing sequences offer relative resistance to many endopeptidases
• The terminal amino acids (N- and C-terminus) are particularly vulnerable to exopeptidase cleavage

2. Structural Modifications

Modern pharmaceutical peptides leverage several engineering strategies to dramatically extend half-life:

• PEGylation: Attaching polyethylene glycol (PEG) chains increases molecular size, reduces renal filtration, and creates a steric barrier against proteases—can extend half-life from minutes to days.
• Fatty acid conjugation (lipidation): The strategy used in semaglutide. Attaching a C18 fatty diacid via a linker to a lysine residue enables binding to albumin, dramatically slowing clearance. This is how semaglutide achieves a 7-day half-life from native GLP-1's 2 minutes.
• D-amino acid substitution: Replacing natural L-amino acids with their mirror-image D-forms creates resistance to proteases (which are stereospecific)—can increase half-life 2-3 fold or more.
• Cyclization: Forming a covalent bond between the N- and C-terminus (or side chains) creates a ring structure that resists exopeptidases and limits protease access.
• Drug Affinity Complex (DAC): Used in CJC-1295 DAC. This technology allows the peptide to bind covalently to serum albumin in vivo, extending half-life from ~30 minutes (CJC-1295 no DAC) to 8–10 days.
• N- and C-terminal capping: Adding acetyl groups (N-terminus) or amide groups (C-terminus) blocks exopeptidase access.

3. Molecular Size

Peptides below approximately 500 Da are rapidly filtered by the kidneys. Larger peptides and proteins resist glomerular filtration. This creates a general trend—larger peptides tend to have longer half-lives—though structural modifications can override this relationship.

4. Administration Route

• Intravenous (IV): 100% bioavailability, fastest plasma peaks, shortest apparent duration due to rapid distribution
• Subcutaneous (SQ): Slower absorption from the injection depot, lower peak concentrations but more sustained plasma levels. Most common route for research peptides.
• Intramuscular (IM): Faster absorption than SQ, more rapid peak concentrations
• Intranasal: Variable absorption via nasal mucosa; for neuropeptides like Semax and Selank, designed to exploit nose-to-brain pathways bypassing systemic circulation

5. Dose and Kinetics

Most peptide pharmacokinetics follow first-order kinetics—the half-life is constant regardless of dose. However, at very high concentrations some peptides may saturate clearance mechanisms, exhibiting non-linear kinetics with longer apparent half-lives.

Peptide Half-Life Reference Table (25+ Peptides)

The following table compiles half-life data from pharmacokinetic studies, manufacturer data, and peer-reviewed literature. Where formal human PK studies are unavailable, estimates are based on animal data. Use the dose plotter for protocol modeling.

Note: Values represent plasma elimination half-life where available. Biological activity windows may extend significantly beyond plasma clearance. Many research-only peptides lack formal human PK studies; figures are derived from animal models and observational data.

Case Study: Why Semaglutide Has a 7-Day Half-Life While Native GLP-1 Has 2 Minutes

The semaglutide story is one of the most instructive examples of how structural engineering can transform a molecule's pharmacology.

Native GLP-1 is a 30-amino acid intestinal peptide with a plasma half-life of approximately 2 minutes. The primary culprit is dipeptidyl peptidase-4 (DPP-4), a ubiquitous enzyme that cleaves the Ala-Glu bond at positions 2-3 of GLP-1, rapidly inactivating it. Renal clearance adds further removal.

Semaglutide's three-modification solution:

1. Substituted alanine at position 8 with aminoisobutyric acid (Aib)—confers DPP-4 resistance
2. Replaced lysine at position 26 with arginine (alternate attachment site)
3. Attached a C18 fatty diacid chain via a hydrophilic spacer to lysine at position 34—enables strong, reversible albumin binding

The albumin binding is the key to the 7-day half-life. Albumin itself has a ~19-day half-life. When semaglutide binds albumin, it is protected from renal filtration and circulating proteases, slowly dissociating to exert its biological effects at GLP-1 receptors.

The same principle explains liraglutide's 13-hour half-life (C16 fatty acid, weaker albumin affinity) vs. semaglutide's 7 days (C18 fatty diacid with optimized linker, stronger sustained binding).

Practical Implications for Research Protocol Design

Use the Peptides.SO dose plotter to model plasma concentration curves. Key principles:

Administration Frequency

Stable steady-state concentrations require dosing at intervals roughly equal to or shorter than the half-life. After approximately 5 half-lives, ~97% of a peptide is cleared.

• Short half-life (<2 hours): BPC-157, GHK-Cu, Sermorelin — require daily or multiple-daily dosing
• Medium half-life (2–24 hours): Ipamorelin, GHRP-2, Liraglutide — daily or twice-daily protocols
• Long half-life (>1 day): Semaglutide, CJC-1295 DAC, Tirzepatide — weekly or biweekly sufficient

Pulsatile vs. Sustained Dosing

For GH secretagogues like Ipamorelin and GHRP-2, pulsatile administration mimicking natural GH release patterns may be preferable to sustained exposure. The ~2-hour half-life of ipamorelin is suited to timed pulse protocols creating discrete GH pulses.

CJC-1295 DAC's 8–10 day half-life produces continuous GHRH receptor stimulation—a fundamentally different pharmacodynamic profile with distinct GH secretion implications in research models.

Washout Timelines (5 Half-Lives to ~97% Clearance)

• BPC-157 (~4 min): ~20 minutes
• Ipamorelin (~2 hours): ~10 hours
• Liraglutide (~13 hours): ~65 hours
• Semaglutide (~7 days): ~35 days
• CJC-1295 DAC (~9 days): ~45 days

Use the half-life calculator for precise washout timelines at any starting concentration.

Why Biological Activity Outlasts Plasma Half-Life

A critical concept: plasma clearance does not equal end of biological effect.

BPC-157 has a plasma half-life measured in minutes, yet animal research documents cellular effects—angiogenesis markers, growth factor upregulation, connective tissue remodeling signals—persisting for days to weeks after administration. This occurs because:

• Receptor occupancy triggers downstream signaling cascades that propagate after the peptide has cleared
• Gene expression changes induced by transient receptor activation persist for hours to days
• Tissue residence times often exceed plasma residence times
• Secondary mediator release—growth factors, cytokines, hormones triggered by the initial peptide interaction—sustains biological effects

This explains why short-half-life peptide research protocols don't require dosing every few minutes to observe sustained outcomes.

Using Peptides.SO Tools for Protocol Modeling

The Dose Plotter visualizes plasma concentration curves given peptide half-life, dose, frequency, and route. It calculates Cmax, steady-state range, time to steady state, and washout timeline. For reconstitution calculations, use the peptide calculator.

Important Limitations

• Limited human PK data: Many research peptides (BPC-157, TB-500, Epithalon, Selank) have never undergone formal human pharmacokinetic studies. Values are estimated from animal models.
• Species differences: Rodent half-life data does not directly translate to human predictions.
• Individual variability: Renal function, hepatic enzyme activity, and body composition all affect clearance in ways population estimates cannot capture.

Half-Life and Storage Stability: What Researchers Need to Know

While peptide half-life is primarily a pharmacokinetic concept describing in vivo clearance rates, the same molecular factors that determine metabolic stability also govern in vitro storage stability. Understanding this connection helps researchers plan storage conditions, reconstitution timing, and protocol scheduling more effectively.

Lyophilized vs. Reconstituted Peptide Stability

The most important storage distinction for research peptides is the physical state of the compound:

In the lyophilized state, peptides are protected from the primary degradation pathways: hydrolysis (requires water), oxidation (greatly slowed at low water activity), and enzymatic cleavage (no proteases present). Once reconstituted, all these degradation mechanisms become active.

How Modification Status Affects Storage Stability

The structural modifications that extend in vivo half-life also influence in vitro storage stability, though through different mechanisms:

• D-amino acid substitutions: Unaffected by proteolysis in storage, but D-amino acids improve resistance to trace contaminants and racemization. Storage stability advantage is modest relative to their pharmacokinetic benefit.
• PEGylation: PEG chains create a hydrophilic shield that reduces aggregation and surface adsorption during storage — a practical advantage when using polypropylene vials or syringes.
• DAC (Drug Affinity Complex): CJC-1295 DAC's albumin-binding modification doesn't significantly affect lyophilized stability, but the longer plasma half-life (8–10 days) means fewer reconstituted vial access events, reducing contamination risk.
• Lipidation (e.g., semaglutide): The fatty acid chain increases hydrophobicity. Lipidated peptides may require specific solubilization steps (mildly alkaline pH, specific solvents) and can be more prone to aggregation at high concentrations during storage.

Temperature and Peptide Degradation Rates

Peptide degradation in solution follows Arrhenius kinetics: each 10°C increase in temperature roughly doubles the degradation rate. This has direct practical implications for storage planning:

• −80°C (ultra-cold): Near-indefinite stability for reconstituted solutions; used for long-term archival. Repeated freeze-thaw cycles cause physical damage (aggregation) — aliquot before freezing.
• −20°C: Suitable for medium-term reconstituted storage (1–6 months depending on peptide) with minimal freeze-thaw cycles.
• 2–8°C (refrigerator): The standard working storage condition for reconstituted peptides. 28–60 days achievable with bacteriostatic water and proper aseptic technique.
• Room temperature: Not recommended for reconstituted peptides. Oxidation of methionine, tryptophan, and cysteine residues accelerates dramatically; hydrolysis of aspartate-proline bonds increases.

Residue Vulnerability in Storage

Just as certain amino acids resist proteolysis (influencing in vivo half-life), specific residues are degradation-prone in storage conditions:

• Methionine: Oxidizes to methionine sulfoxide — accelerated by light and dissolved oxygen. Use amber vials or nitrogen headspace for methionine-containing peptides.
• Cysteine: Forms disulfide bonds with other cysteine residues or free thiols in solution. Disulfide scrambling can inactivate peptides during storage.
• Asparagine (Asn): Deamidates to aspartate at neutral-to-basic pH — a significant issue for peptides stored in PBS or at physiological pH. Store at slightly acidic pH when possible.
• Tryptophan: Oxidizes in the presence of light and reactive oxygen species. Light-protect vials containing tryptophan-bearing peptides.

Peptides with fewer of these vulnerable residues — or with protective modifications — demonstrate better storage stability, just as they tend to have longer plasma half-lives due to similar resistance to enzymatic attack. The connection is not coincidental: both phenomena reflect the same fundamental chemistry of peptide bond and side-chain stability.

Practical Rule: Map Half-Life to Storage Risk

A practical framework for storage planning: peptides with very short plasma half-lives (< 30 minutes, such as BPC-157 and native GLP-1) are typically unmodified and thus also more vulnerable to in vitro degradation. Heavily modified peptides with long plasma half-lives (semaglutide at 7 days, CJC-1295 DAC at 8–10 days) have engineered resistance to degradation that confers some storage advantages in reconstituted form.

For high-value or short-lived peptides, plan to use reconstituted aliquots quickly (within 7–14 days), store at the coldest appropriate temperature, and avoid repeated freeze-thaw cycles. For modified long-half-life peptides, reconstituted storage in bacteriostatic water at 4°C for 28–60 days is generally acceptable.

Use our peptide calculator to track reconstitution dates and concentration alongside half-life calculations for your research protocols.

Summary

Peptide half-life spans from native GLP-1 at 2 minutes to CJC-1295 DAC at 8–10 days—a difference driven entirely by structural engineering. Key principles:

• Unmodified peptides are short-lived due to proteases and renal filtration
• Lipidation, PEGylation, D-amino acids, cyclization, and DAC technology dramatically extend plasma stability
• Biological activity windows often far exceed plasma half-life
• Route of administration (SQ vs. IM vs. intranasal) affects absorption kinetics and apparent duration
• Many research peptides lack rigorous human PK data—treat published figures as estimates

Model your research protocols with the dose plotter and half-life calculator.

For research purposes only. This content is educational and does not constitute medical advice.

---

Further Reading:

• •Khavinson Bioregulatory Peptides: Complete Guide to Short-Chain Tissue-Specific Peptide Research (2026)
• •Peptide Degradation Pathways: Complete Guide to Chemical Stability and Prevention
• •Peptide Bioconjugation Strategies: PEGylation, Lipidation, and Beyond for Half-Life Extension
• •Venom-Derived Peptides: From Evolutionary Weapons to Precision Research Tools
• •Reconstitution Calculator
• •Peptide Stack Builder